Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data

Mark Cotton, Haseena Cassim, Noris Pavía-Ruz, Harmony P Garges, Teodora Perger, Susan L Ford, Mary Beth Wire, Naomi Givens, Lisa L Ross, Yu Lou, Jörg Sievers, Katharine Cheng, Mark Cotton, Haseena Cassim, Noris Pavía-Ruz, Harmony P Garges, Teodora Perger, Susan L Ford, Mary Beth Wire, Naomi Givens, Lisa L Ross, Yu Lou, Jörg Sievers, Katharine Cheng

Abstract

Background: Pharmacokinetics, safety and antiviral activity of fosamprenavir (FPV) with ritonavir (RTV) twice daily were evaluated in HIV-1-infected infants and children 4 weeks to <2 years over 48 weeks.

Methods: Results from intensive pharmacokinetic sampling of subjects enrolled in single dose visits was used to determine individualized dosing for the first 6-10 subjects in each of 2 cohorts (4 weeks to <6 months, 6 months to <2 years); steady state pharmacokinetic data were then used to select the dosage regimen for the remaining subjects recruited to the cohort. Intensive pharmacokinetic sampling was performed at week 2 or 8; predose samples were collected every 4-12 weeks thereafter. Safety and plasma HIV-1 RNA were monitored every 4-12 weeks.

Results: Fifty-nine subjects received study medication. FPV 45 mg/kg boosted with RTV 7 to 10 mg/kg BID achieved average plasma amprenavir area under curve(0-τ) values 26% to 28% lower and Cmax similar to historical adult data for FPV/RTV 700/100 mg BID; amprenavir Cτ values were lower in the subjects <6 months of age. At week 48, 35 of 54 (65%) subjects had achieved plasma HIV-1 RNA <400 copies/mL and 33 of 54 (61%) had plasma HIV-1 RNA values <50 copies/mL. The most common adverse events were diarrhea, upper respiratory tract infection, gastroenteritis and otitis media.

Conclusions: Final FPV/RTV dosing regimens achieved plasma amprenavir exposures comparable with those from regimens approved in adults, with the exception of trough exposures in the <6-month-old infants. The FPV/RTV regimens led to viral suppression in 61% of patients and were generally well tolerated.

Conflict of interest statement

M.C. received support from a grant from ViiV Healthcare and payment for lectures, including service on speakers’ bureaus, from Abbott Laboratories. H.P.G., T.P., S.L.F., M.B.W., N.G., L.L.R., Y.L., J.S. and K.C. are employees of GlaxoSmithKline.

References

    1. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT Study: A 48-week open-label study to compare the antiviral efficacy and safety of GW43908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. JAIDS. 2004;35:22–32.
    1. Gathe JC, Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529–1537.
    1. DeJesus E, Lamarca A, Sension M, et al. In: 10th Conference on Retroviruses and Opportunistic Infections (CROI) Boston, MA: February 10–14, 2003. The Context Study: Efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). Abstract 178.
    1. Lexiva. US Prescribing Information. 2012
    1. DAIDS Toxicity Tables 1994. Tables for grading severity of pediatric adverse experiences (≤3 months of age and >3 months of age). Available at: and . Accessed May 13, 2013.
    1. DAIDS Toxicity Tables. Tables for grading severity of pediatric adverse experiences Version 1.0, December 2004. Division of AIDS, NIAID. Available at: . Accessed September 16, 2011.
    1. Chadwick E, Borkowsky W, Fortuny C, et al. Safety and antiviral activity of fosamprenavir/ritonavir once daily regimens in HIV-infected pediatric subjects ages 2 to18 years (48-week interim data, Study APV20003). 14th Conference on Retroviruses and Opportunistic Infections (CROI) 2007. Los Angeles, CA; February 25–28, 2007; Poster 719.
    1. HIV Drug Resistance Mutations. Available at: . Accessed March 21, 2011.
    1. Pérez-Elías MJ, Morellon ML, Ortega E, et al. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrob Agents Chemother. 2009;53:5185–5196.
    1. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother. 2002;46:746–754.
    1. Sadler BM, Piliero PJ, Preston SL, et al. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose co-administration to healthy volunteers. AIDS. 2001;15:1009–1018.
    1. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet. 2002;41:1077–1094.
    1. Kearns GL, Robinson PK, Wilson JT, et al. Pediatric Pharmacology Research Unit Network. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther. 2003;74:312–325.
    1. Voronin E, Fortuny C, Perez-Tamarit D, et al. Pharmacokinetics, safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2 to 18 year-old children (48-week data, Study APV29005, a prospective, open-label, multi-centre, 48-week cohort study) [Abstract MOPE049].. 19th International AIDS Conference (IAC ). Washington, DC; July 22–27, 2012.
    1. Chadwick EG, Yogev R, Alvero CG, et al. International Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS. 2011;25:643–649.
    1. Torres HA, Arduino RC. Fosamprenavir calcium plus ritonavir for HIV infection. Expert Rev Anti Infect Ther. 2007;5:349–363.
    1. Eron J, Jr, Yeni P, Gathe J, Jr, et al. KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476–482.
    1. Chadwick EG, Rodman JH, Britto P, et al. PACTG Protocol 345 Team. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J. 2005;24:793–800.
    1. Sáez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:216–224.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe